Literature DB >> 7152525

Familial lecithin-cholesterol acyltransferase deficiency in a Japanese family: evidence for functionally defective enzyme in homozygotes and obligate heterozygotes.

J J Albers, C H Chen, J Adolphson, M Sakuma, T Kodama, Y Akanuma.   

Abstract

Lecithin-cholesterol acyltransferase (LCAT) mass and activity were measured in a Japanese family with familial LCAT deficiency. The two LCAT-deficient subjects had LCAT mass approximately 40-46% of normal (2.65 and 2.31 micrograms/ml respectively, as compared with normal levels of 5.76 +/- 0.95 microgram/ml in 19 Japanese subjects) and enzyme activity less than 10% of normal (9.1 and 8.3 nmol/h/ml respectively, as compared with normal levels of 100 nmol/h/ml). All obligate heterozygotes examined, including the father of the two LCAT-deficient subjects, and all five children of the deficient subjects had LCAT mass approximately 72-80% of the normal LCAT mass (4.12, 4.38, 4.45, 4.48, 4.49, 4.61 micrograms/ml, respectively) and LCAT activity approximately half normal (51.9, 52.4, 54.2, 56.6, and 57.2 nmol/h/ml). We conclude that the two LCAT-deficient subjects of this family have functionally defective enzyme. Furthermore, the data suggest that the plasma of the obligate heterozygotes contain both normal and functionally defective enzymes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7152525     DOI: 10.1007/bf00295608

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  12 in total

1.  A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

Authors:  G R Warnick; J J Albers
Journal:  J Lipid Res       Date:  1978-01       Impact factor: 5.922

2.  Characterization and immunoassay of apolipoprotein D.

Authors:  J J Albers; M C Cheung; S L Ewens; J H Tollefson
Journal:  Atherosclerosis       Date:  1981-06       Impact factor: 5.162

3.  Familial lecithin-cholesterol acyltransferase deficiency in four Norwegian Families. Evidence for low levels of a functionally defective enzyme.

Authors:  J J Albers; E Gjone; J L Adolphson; C H Chen; P Teisberg; H Torsvik
Journal:  Acta Med Scand       Date:  1981

4.  Quantitation of apolipoprotein A-I of human plasma high density lipoprotein.

Authors:  J J Albers; P W Wahl; V G Cabana; W R Hazzard; J J Hoover
Journal:  Metabolism       Date:  1976-06       Impact factor: 8.694

5.  Immunoassay of human plasma apolipoprotein B.

Authors:  J J Albers; V G Cabana; W R Hazzard
Journal:  Metabolism       Date:  1975-12       Impact factor: 8.694

6.  Population-based reference values for lecithin-cholesterol acyltransferase (LCAT).

Authors:  J J Albers; R O Bergelin; J L Adolphson; P W Wahl
Journal:  Atherosclerosis       Date:  1982-06       Impact factor: 5.162

7.  Genetic control of lecithin-cholesterol acyltransferase (LCAT): measurement of LCAT mass in a large kindred with LCAT deficiency.

Authors:  J J Albers; G Utermann
Journal:  Am J Hum Genet       Date:  1981-09       Impact factor: 11.025

8.  Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin: cholesterol acyltransferase activity.

Authors:  C H Chen; J J Albers
Journal:  J Lipid Res       Date:  1982-07       Impact factor: 5.922

9.  Familial lecithin-cholesterol acyltransferase: identification of heterozygotes with half-normal enzyme activity and mass.

Authors:  J J Albers; C Chen; J L Adolphson
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

10.  Radioimmunoassay of human plasma lecithin-cholesterol acyltransferase.

Authors:  J J Albers; J L Adolphson; C H Chen
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

View more
  1 in total

Review 1.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.